Previous 10 | Next 10 |
2024-01-09 01:07:03 ET Summary Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aq...
2024-01-04 07:17:03 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Call Transcript Xeris Pharmaceuticals GAAP EPS of -$0.09 beats by $0.03, revenue of ...
Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M Company to report Q...
2024-01-01 03:06:21 ET Summary Xeris Biopharma has shown strong revenue growth, from $2.7 million in 2019 to $152.7 million in the 12 months trailing to September 2023. The company's ready-to-use glucagon drug, Gvoke, has the potential for significant sales, especially in the US w...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...
2023-11-17 13:32:10 ET Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch. Why Insider Buying Matters in Penny S...
--News Direct-- Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results. With three growing products addressing severe hypoglycemia, Cushing's Syn...
2023-11-16 10:54:48 ET Penny stocks , usually under $5 a share, draw traders looking for big gains. But these stocks can be risky. A smart move is to watch insider trading through SEC filings. Insiders like company directors and officers have access to key info that isn’t public....
2023-11-16 10:00:07 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: XWELL, Xeris B...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
The Dow Jones index closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....
Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide ...